Internet-based Group Contingency Management to Promote Smoking Abstinence

September 23, 2014 updated by: Jesse Dallery, National Development and Research Institutes, Inc.
The purpose of the study is to develop and test an Internet-based group contingency management program designed to promote smoking cessation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Florida
      • Gainesville, Florida, United States, 32611
        • University of Florida
    • New York
      • New York City, New York, United States, 10010
        • National Development and Research Institutes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • self-reported smoker
  • ability to use the Internet
  • permission to contact applicant by phone

Exclusion Criteria:

  • self-report of a history of or current severe or unstable medical or psychiatric illness that would interfere with the study
  • inability to avoid high levels of ambient CO (e.g., occupational exposure; lives with a another smoker who smokes in the home)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Full Group Contingency
This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
Behavioral: Full Group Contingency
This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
Experimental: Mixed Group Contingency
This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
Behavioral: Mixed Group Contingency
This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Breath CO
Time Frame: 8 weeks
Twice daily breath CO samples obtained during baseline and treatment
8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Point prevalence measure of abstinence
Time Frame: at the end of treatment (approximately week 4) and at 3 month follow-up
Abstinence will be defined as: (a) CO sample ≤ 4 ppm; (b) cotinine < 50 ng/ml; and (c) reporting not smoking, not even a puff in the last 7 days.
at the end of treatment (approximately week 4) and at 3 month follow-up
Duration of abstinence during treatment.
Time Frame: 3 weeks
The longest duration of sustained abstinence (CO ≤ 4 ppm) based on the twice-daily breath samples during the treatment period.
3 weeks
Rate of social exchanges
Time Frame: 3 weeks
The number of comments posted on the discussion forum during treatment.
3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Development and Research Institutes, Inc.

Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Jesse Dallery, PhD, National Development and Research Institutes, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2010

Primary Completion (Actual)

August 1, 2013

Study Completion (Actual)

August 1, 2013

Study Registration Dates

First Submitted

August 12, 2010

First Submitted That Met QC Criteria

August 12, 2010

First Posted (Estimate)

August 13, 2010

Study Record Updates

Last Update Posted (Estimate)

September 25, 2014

Last Update Submitted That Met QC Criteria

September 23, 2014

Last Verified

September 1, 2014

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 1R21DA029162 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cigarette Smoking

Clinical Trials on Full Group Contingency

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe